Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
[content-module:CompanyOverview|NYSE:T]

Investor focus on AT&T (NYSE: T) is starting to sharpen, with the company’s stock price making a healthy upward move of nearly 50% over the past year as of

How Does D-Wave Stack Up Against Quantum Competitors?
How Does D-Wave Stack Up Against Quantum Competitors?
[content-module:CompanyOverview|NYSE:QBTS]

D-Wave Quantum Inc. (NYSE: QBTS) has emerged as one of the most talked-about stocks in the quantum computing industry, a space investors are watching

iTeos verkündet Topline-Zwischenergebnisse der GALAXIES Lung-201-Studie für die First-Line-Behandlung mit Belrestotug und Dostarlimab von Krebspatienten, die von einem nicht-kleinzelligen Lungenkarzinom mit hoher PD-L1-Expression betroffen sind: https://upload.wikimedia.org/wikipedia/commons/thumb/3/32/GSK_logo_2022.svg/1024px-GSK_logo_2022.svg.png
iTeos verkündet Topline-Zwischenergebnisse der GALAXIES Lung-201-Studie für die First-Line-Behandlung mit Belrestotug und Dostarlimab von Krebspatienten, die von einem nicht-kleinzelligen Lungenkarzinom mit hoher PD-L1-Expression betroffen sind

– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben

– Ausgehend von der Gesamtheit der Daten haben sich iTeos und

Tempus AI Stock: Time to Double Down or Cut and Run?
Tempus AI Stock: Time to Double Down or Cut and Run?
[content-module:CompanyOverview|NASDAQ:TEM]

Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians

AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?
AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?

For the big three players in the United States telecom sector, Q1 earnings are in the books. Verizon Communications (NYSE: VZ), T-Mobile (NASDAQ: TMUS), and AT&T (NYSE: T) are by far the most

3 Dividend Kings Outshining the Market in 2025
3 Dividend Kings Outshining the Market in 2025

So far, 2025 hasn't exactly been kind to investors. The S&P 500 is down 5.5% year-to-date, weighed down by mounting uncertainty, tariffs, fears of an economic slowdown, and concerns over stretched

AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround
AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround

AT&T Inc. (NYSE: T) delivered a solid first-quarter 2025 earnings report that showcased significant momentum in its core connectivity businesses, underpinning a cautiously optimistic outlook for

AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
AST SpaceMobile: 5 Reasons to Buy This Tiny Trailblazer Stock
[content-module:CompanyOverview|NASDAQ:ASTS]

AST SpaceMobile Inc. (NASDAQ: ASTS) is developing the world’s first space-based cellular broadband network, with direct-to-device (D2D) technology

Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold
Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold

Insiders bought large caps like Texas Pacific Land (NYSE: TPL), TKO Group (NYSE: TKO), and Keurig Dr Pepper (NASDAQ: KDP) in Q1, highlighting opportunities in their stocks. The question for Q2 is

Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
[content-module:CompanyOverview|NASDAQ:SURG]

SurgePays (NASDAQ: SURG) stock surged more than 70% after it issued solid guidance. That is the one reason to buy. The company expects the Q1 and

Avacta Stock: Cancer Drug Shows Promising Results
Avacta Stock: Cancer Drug Shows Promising Results

The British biotechnology firm Avacta Therapeutics has reported significant progress with its lead drug candidate AVA6000, a modified form of the chemotherapy drug doxorubicin. In a recently

AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies
AstraZeneca Stock: Strategic Expansion in Chinese Market Intensifies

AstraZeneca is bolstering its presence in the Chinese healthcare sector through a strategic acquisition worth $160 million, purchasing FibroGen's Chinese subsidiary. The deal, structured with an

Hims & Hers: From Viral Ad to Volatile Stock
Hims & Hers: From Viral Ad to Volatile Stock

Hims & Hers Health's (NYSE: HIMS) share price has surged recently, climbing above $60 and creating new 52-week and all-time record highs for the company. This significant increase in Hims & Hers

Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside
Novo Nordisk Shares Near New 52-Week Low: Analysts See Big Upside

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 weeks. Shares are down 34% over that period as of the Feb. 13 close. The

Merus wird beim 2025 Virtual Oncology Leadership Summit von Citi eine Präsentation halten
Merus wird beim 2025 Virtual Oncology Leadership Summit von Citi eine Präsentation halten

UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative

Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Beyond Rigetti: Top 3 Quantum Computing Stock Picks

Just when you may have finally gotten your head around the opportunity in artificial intelligence (AI), a new investment opportunity has popped up. Quantum computing is the latest “new thing”

Telecom Titans: Comparing Verizon and AT&T for Growth Potential
Telecom Titans: Comparing Verizon and AT&T for Growth Potential

When it comes to stocks that can offer both income and upside, two of the world’s largest telecom companies are interesting places to look. Verizon Communications (NYSE: VZ) and AT&T (NYSE: T)

3 REITs With Big Dividend Growth and Sustainable Payouts
3 REITs With Big Dividend Growth and Sustainable Payouts

When it comes to earning investment income, one of the most relevant investment vehicles is Real Estate Investment Trusts (REITs). REITs must distribute at least 90% of their taxable earnings out

EMGA sichert sich 90 Mio. US-Dollar von der EIB für die brasilianische BTG Pactual
EMGA sichert sich 90 Mio. US-Dollar von der EIB für die brasilianische BTG Pactual

LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Emerging Markets Global Advisory LLP (EMGA) gibt heute bekannt, eine Fremdfinanzierung in Höhe von 90 Millionen US-Dollar für ihren langjährigen

Can ASTS Stock Beat the Market in 2026?: https://g.foolcdn.com/editorial/images/844184/gettyimages-1951614109-1200x800-5b2df79.jpg
Can ASTS Stock Beat the Market in 2026?

AST SpaceMobile (NASDAQ: ASTS) was a bad investment from 2020 to the start of 2024. The stock woefully underperformed the S&P 500 during that stretch and went from $20 per share to $2 per share

2 Stocks Up Over 600% in the Past 3 Years With More Room to Run: https://g.foolcdn.com/editorial/images/845154/person-raising-two-fists-in-the-air.jpg
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run

Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over

Why a $27 Million Buy Signals New Confidence in Weatherford Stock: https://cdn.content.foolcdn.com/images/1umn9qeh/production/280eca1b4ecd8cc2401a2f4b2c3a68395e00dc85-1401x1251.png?w=1401&h=1251
Why a $27 Million Buy Signals New Confidence in Weatherford Stock

Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/34d887ed4212e8f7cd62f3cec35549f0cf9a39c0-1401x1251.png?w=1401&h=1251
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?

On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest

Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock: https://cdn.content.foolcdn.com/images/1umn9qeh/production/37a7f80f063688ddbd3b84d74a534e9e7a0367b6-1401x1251.png?w=1401&h=1251
Why a Value Fund Has a $29 Million Bet on Core Natural Resources Stock

New York City-based Summit Street Capital Management increased its stake in Core Natural Resources (NYSE:CNR) by 81,170 shares in the third quarter, adding approximately $10.4 million in position

Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/1a599f395be31e2f508c3aa7decb988f9ce983b7-1401x1251.png?w=1401&h=1251
Is Kulicke and Soffa Stock a Buy Even as One Fund Dumps a $10 Million Stake?

New York City-based Summit Street Capital Management fully exited its position in Kulicke and Soffa Industries, Inc. (NASDAQ:KLIC), reducing holdings by 281,812 shares during the quarter and